It is time to buy the shares. On 28 February they will report the fourth quarter. I expect very good news, but this is irrelevant. You can see that there is a turning point in the chart. The first target is around 15.20, then it is going to refill the gap.
And of course in the long term, this short is very bullish.
CPRX - waiting for short position.
Market almost touched a higher Lin Reg and above MACD on D1.
Confirmation: NOT YET !!!!.
Red box: Buy area.
Suggested TP: Tp1 at $10.40(close 50% of the position) and 2nd at $5.80.
Suggested SL: Always follow the Ratio - min 1:3
Warning!!!!
This content should not be interpreted as financial advice.
As per the image. Key points selling points highlighted in red.
Key reinforment poins (long) highlighted in green.
Good profit may come your way!
I still believe the full correction is yet to come. we may be taking about a couple of weeks away. But it has strong cofirmation points to watch out for
CPRX is the #1 stock in the biotech group by almost every metric. The table on the chart shows its ranking out of all 795 biotech stocks by 3 metrics from IBD's MarketSmith.
Sales and earnings are surging and the rate at which both are growing has increased in each of the last 4 quarters.
The stock made a false breakout on December 14 when the market gapped up...
Notes:
* Strong up trend
* Okay earnings track record
* Basing for the past ~8 weeks
* Pulled back to its 10 week line and managed to hold it as support creating a cup and handle pattern
* Printed a pocket pivot near its 50 day line offering an early entry and indicating institutional demand
Technicals:
Sector: Healthcare - Biotechnology
Relative Strength...
Ascending Triangles are a bullish pattern
This is demonstrated by CPRX with a strong breakout
Price from here can either retest or continue its breakout
When markets are messy I like to explore long term bases in relatively unknown stocks.
CPRX has a 15 year base with contracting volatility in recent years, mostly since 2019.
I like the look of the quarterly chart and I like the volume markers on the daily - institutional funds have been progressively accumulating.
As all biotech stocks are highly...
Catalyst Pharma (CPRX) is an absolute monster. Not only is the company posting huge sales and earnings growth in a sector that rarely has either, the stock has more than doubled over the last few months.
There are 801 stocks in the biotech group tracked by Investors Business Daily, and CPRX ranks at the very top (see image in chart).
After such a large advance...
Notes:
* Strong up trend
* Not the best earnings
* Tested historical resistance of $6.17 around mid June
* Broke and retested historical resistance of $7.43 just recently
* Printed a pocket pivot and is still relatively close to its 50 day line
* The Healthcare sector is doing relatively well compared to others
Technicals:
Sector: Healthcare -...
(NASDAQ:CPRX) makes a drug called Firdapse for Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder. Since the drug's first sales in 2019, the company's quarterly revenue has exploded by a shocking 7,090%. And in the coming years, that revenue could grow even more.
Now, Catalyst is focused on expanding Firdapse's approved indications to cover...
Hello Traders! CPRX was making a pull back and would expect a nice bounce at the strong support level after a strong bullish reversal candle.
What I did to this analysis:
1. I Draw Major Support/Resistance in Weekly Time frame
2. Find trend - Higher High, Higher Low
3. Find a pullback in price
4. Wait for the Strong Reversal Candle at Support Level
In...
